Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13695Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chitkara, Deepak | - |
| dc.date.accessioned | 2024-01-05T10:57:23Z | - |
| dc.date.available | 2024-01-05T10:57:23Z | - |
| dc.date.issued | 2022-08 | - |
| dc.identifier.uri | https://link.springer.com/article/10.1007/s12247-022-09677-3 | - |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13695 | - |
| dc.description.abstract | Docetaxel (DTX) is one of the anti-neoplastic drugs widely employed in breast cancer management. Along with advantages, several challenges are associated with administering the BCS class IV drugs like DTX. Looking into the promises of various nanotechnology-based drug delivery systems, it was envisioned to explore the influence of carrier type on the drug delivery outcome for this anticancer agent. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Springer | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Drug Delivery | en_US |
| dc.subject | Nanocarriers | en_US |
| dc.subject | Docetaxel (DTX) | en_US |
| dc.subject | Anticancer therapy | en_US |
| dc.title | Influence of Nanocarrier Type on the Drug Delivery Aspects of Docetaxel: Empirical Evidences | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | Department of Pharmacy | |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.